Clinical Trials

377 enrolled

Fallopian Tube Neoplasms, Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT03742895 2026-05-15

MK-7339-002

329 enrolled

Advanced Solid Neoplasms

NCT01081951 2026-05-13

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT03459846 2026-05-11

BAYOU

154 enrolled 13 charts

Urinary Bladder Neoplasms

NCT06909825 2026-05-06

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

85 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05005728 2026-05-05

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

72 enrolled

Prostatic Neoplasms

NCT03775486 2026-05-01

ORION

401 enrolled 26 charts

Thoracic

Non-small Cell Lung Cancer NSCLC

NCT04123366 2026-04-22

MK-7339-007

300 enrolled

Other solid neoplasm

Solid Tumors

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT03334617 2025-10-27

HUDSON

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04644289 2025-10-03

WoO

60 enrolled

Carcinoma, Ovarian Epithelial

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

BreastGastrointestinalGenitourinaryGynecologic

298 enrolled 18 charts

Ovarian

NCT05498155 2025-06-10

OlympiaN

50 enrolled

Breast Neoplasms

NCT06686030 2025-04-16

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

150 enrolled

Platinum-sensitive Ovarian Cancer

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

72 enrolled 29 charts

Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT00494234 2024-01-19

ICEBERG 1

BreastClassical hematology

54 enrolled 17 charts

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

158 enrolled 32 charts

Prostatic Neoplasms

NCT04669002 2023-08-02

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

34 enrolled

Ovarian Neoplasms

NCT01063517 2023-07-20

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

124 enrolled 27 charts

Gastrointestinal

Stomach Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

99 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Phase 2 Withdrawn

GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02983799 2022-04-13

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

272 enrolled 14 charts

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

62 enrolled 15 charts

Ovarian Neoplasms

NCT04239014 2021-03-10

DUETTE

Phase 2 Withdrawn

Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Classical hematologyGynecologic

97 enrolled 22 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

Classical hematologyGynecologic

58 enrolled 13 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00912743 2016-11-09

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status